Special Issue

Nanotechnology Applied in Prevention, Diagnosis and Treatment of Cancer

Message from the Guest Editor

Cancer is a major global health issue. Indeed, despite significant progress made in the fields of cancer research and treatment, there remains a need for more effective and precise diagnostic tools and treatment options. Nanotechnology, the manipulation of materials at the nanoscale level, has the potential to revolutionize cancer care by offering innovative approaches for prevention, diagnosis, and treatment. Nanoparticles can be engineered to selectively target cancer cells while minimizing side effects, whether as drug carriers or imaging agents. In cancer prevention, nanotechnology may help to reduce the incidence of the disease by developing novel approaches to address risk factors and early detection. The impact of nanotechnology in cancer care has shown promising results in preclinical and clinical studies. However, further research and development are necessary to realize its full potential in cancer care. Nanotechnology presents a unique opportunity to develop more effective and precise cancer therapies, which may in turn lead to better outcomes for patients. We look forward to receiving your contributions.

Guest Editor

Dr. Hyun-Ouk Kim

Department of Biotechnology and Bioengineering, Kangwon National University, Chuncheon 24341, Gangwon-do, Republic of Korea

Deadline for manuscript submissions

closed (20 June 2025)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/165952

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

